Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 8/20 | 0.50 |
| ▸ | CTSC | P53634 | 3/20 | 0.46 |
| ▸ | GHSR | Q92847 | 1/20 | 0.41 |
| ▸ | CALCRL | Q16602 | 1/20 | 0.40 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.39 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.39 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14903400 | 1.00 | REN (0.50) | RENCTSCGHSRCALCRLMAPK8 | |
| SCHEMBL14903320 | 0.87 | CTSC (0.52) | RENCTSCGHSRCALCRL | |
| SCHEMBL14903448 | 0.87 | CTSC (0.52) | RENCTSCGHSRCALCRL | |
| SCHEMBL14903433 | 0.82 | CTSC (0.52) | RENCTSC | |
| SCHEMBL14903295 | 0.82 | CTSC (0.52) | RENCTSC | |
| SCHEMBL30578479 | 0.80 | CTSC (0.54) | RENCTSCGHSRCALCRL | |
| SCHEMBL30546877 | 0.80 | CTSC (0.63) | RENCTSCGHSR | |
| SCHEMBL29701979 | 0.80 | CTSC (0.63) | RENCTSCGHSR | |
| SCHEMBL29702042 | 0.80 | CTSC (0.63) | RENCTSCGHSR | |
| SCHEMBL14906489 | 0.79 | CTSC (0.49) | RENCTSCGHSRCALCRL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170157204-A1 | CYCLIC TETRAPEPTIDES AND THERAPEUTIC APPLICATIONS THEREOF | LODZ UNIVERSITY OF TECHNOLOGY (PL) | 2017-06-08 | — | — | US | disclosed |
| US-9382292-B2 | Cyclic tetrapeptides and therapeutic applications thereof | PEPTADERM SP. Z O.O. (PL) | 2016-07-05 | — | — | US | disclosed |
| US-20130108655-A1 | CYCLIC TETRAPEPTIDES AND THERAPEUTIC APPLICATIONS THEREOF | PEPTADERM SP. Z O.O. (PL) | 2013-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170157204-A1 | CYCLIC TETRAPEPTIDES AND THERAPEUTIC APPLICATIONS THEREOF | PNISR, APLNR, VIP | REN 119/4885CTSC 419/4885GHSR 451/4885 |
| US-20130108655-A1 | CYCLIC TETRAPEPTIDES AND THERAPEUTIC APPLICATIONS THEREOF | PNISR, APLNR, VIP | REN 119/4885CTSC 419/4885GHSR 451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.